GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novartis AG (STU:NOTA) » Definitions » 5-Year Sharpe Ratio

Novartis AG (STU:NOTA) 5-Year Sharpe Ratio : 0.40 (As of Jun. 29, 2025)


View and export this data going back to . Start your Free Trial

What is Novartis AG 5-Year Sharpe Ratio?

The 5-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past five years. As of today (2025-06-29), Novartis AG's 5-Year Sharpe Ratio is 0.40.


Competitive Comparison of Novartis AG's 5-Year Sharpe Ratio

For the Drug Manufacturers - General subindustry, Novartis AG's 5-Year Sharpe Ratio, along with its competitors' market caps and 5-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novartis AG's 5-Year Sharpe Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novartis AG's 5-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Novartis AG's 5-Year Sharpe Ratio falls into.


;
;

Novartis AG 5-Year Sharpe Ratio Calculation

The 5-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset in the last five years. A stock / portfolio's 5-Year Sharpe Ratio can be calculated by dividing the difference between the five-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the investment returns over the past five years.


Novartis AG  (STU:NOTA) 5-Year Sharpe Ratio Explanation

The 5-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past five years. It is calculated as the annualized result of the average five-year monthly excess returns divided by its standard deviation in the five-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.


Novartis AG 5-Year Sharpe Ratio Related Terms

Thank you for viewing the detailed overview of Novartis AG's 5-Year Sharpe Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Novartis AG Business Description

Address
Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.

Novartis AG Headlines

No Headlines